What was the outcome of the REDUCE-IT trial?
The REDUCE-IT trial showed a 25% reduction in the primary end point of MACEs (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina). Results for nonfatal stroke and TIA were the same for MACEs. No difference occurred in hemorrhagic stroke. A small, significant increase in AF occurred in those treated with IPE (5.3% versus 3.9%).